Conventional vs. newer antipsychotics in elderly patients

Bulletin of the Menninger Clinic

Volumn 63, Issue 2 SUPPL. A, 1999, Pages

  Jeste, Dilip V ^a,b   Rockwell, Enid ^a   Harris, M Jackuelyn ^a   Lohr, James B ^a   Lacro, Jonathan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE;

AGING; AGITATION; COGNITION; CONFUSION; CONSTIPATION; DEMENTIA; DOSE RESPONSE; DROWSINESS; DRUG COST; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; GLAUCOMA; HUMAN; NEGATIVE SYNDROME; OBESITY; ORTHOSTATIC HYPOTENSION; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; URINE RETENTION; VERTIGO; XEROSTOMIA;

EID: 0032935354     PISSN: 00259284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Arvanitis, L. A., Miller, B. G., & the Seroquel Trial 13 Study Group. (1997). Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry, 42, 233-246.
2. Berman, I., Merson, A., Rachov-Pavlov, J., et al. (1996). Risperidone in elderly schizophrenic patients: An open-label trial. American Journal of Geriatric Psychiatry, 4, 173-179.
3. Chengappa, K. N. R., Baker, R. W., Kreinbrock, S. B., et al. (1995). Clozapine use in female geriatric patients with psychoses. Journal of Geriatric Psychiatry and Neurology, 8, 12-15.
4. Factor, S. A., & Brown, D. (1992). Clozapine prevents recurrence of psychosis in Parkinson's disease. Movement Disorders, 7, 125-131.
5. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
6. Gilbert, P. L., Harris, M. J., McAdams, L. A., et al. (1995). Neuroleptic withdrawal in schizophrenic patients. Archives of General Psychiatry, 52, 173-188.
7. Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
8. Green, M. F., Marshall, B. D., Wirshing, W. C., et al. (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry, 154, 799-804.
9. Hargreaves, W. A., & Shumway, M. (1996). Pharmacoeconomics of antipsychotic drug therapy. Journal of Clinical Psychiatry, 57, 66-76.
10. Harris, M. J., Heaton, R. K., Schalz, A., et al. (1997). Neuroleptic dose reduction in older psychotic patients. Schizophrenia Research, 27, 241-248.
11. Hoff, A. L., Faustman, W. O., Wieneke, M., et al. (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15, 361-369.
12. Jeste, D. V., Caligiuri, M. P., Paulsen, J. S., et al. (1995). Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 patients. Archives of General Psychiatry, 52, 756-765.
13. Jeste, D. V., Eastham, J. H., Gierz, M., et al. (1997). Use of risperidone in the elderly. In F. J. Ayd (Ed.), The art of rational risperidone therapy (pp. 147-167). Baltimore: AYD Medical Communications.
14. Jeste, D. V., Eastham, J. H., Lacro, J. P., et al. (1996). Management of late-life psychosis. Journal of Clinical Psychiatry, 57(suppl. 3), 39-45.
15. Jeste, D. V., Lacro, J. P., Gilbert, P. L., et al. (1993). Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin, 19(4), 817-830.
16. Jeste, D. V., Lohr, J. B., Eastham, J. H., et al. (in press). Adverse neurobiological effects of long-term use of neuroleptics: Human and animal studies. Journal of Psychiatric Research.
17. Kahn, N., Freeman, A., Juncos, J. L., et al. (1991). Clozapine is beneficial for psychosis in Parkinson's disease. Neurology, 41, 1699-1700.
18. Kane, J. M., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
19. Kane, J. M., Woerner, M., & Lieberman, J. (1988). Tardive dyskinesia: Prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology, 8(4), S2S-56S.
20. Kane, J. M., Woerner, M. G., Pollack, S., et al. (1993). Does clozapine cause tardive dyskinesia? Journal of Clinical Psychiatry, 54, 327-330.
21. Klapow, J. C., Evans, J., Patterson, T. L., et al. (1997). Direct assessment of functional status in older patients with schizophrenia. American Journal of Psychiatry, 154, 1022-1024.
22. Marder, S. R., & Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
23. Meltzer, H. Y., Cola, P., Way, L., et al. (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.
24. Meltzer, H. Y., & Fibiger, H. C. (1996). Olanzapine: A new atypical antipsychotic drug. Neuropsychopharmacology, 14, 83-85.
25. National Institute of Mental Health. (1975). Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom, 4, 3-6.
26. Saltz, B. L., Woerner, M. G., Kane, J. M., et al. (1991). Prospective study of tardive dyskinesia incidence in the elderly. JAMA, 266, 2402-2406.
27. Salzman, C., Vacarro, B., Lieff, J., et al. (1995). Clozapine in older patients with psychosis and behavioral disruption. American Journal of Geriatric Psychiatry, 3, 26-33.
28. Schooler, N., & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486-487.
29. Small, J. G., Hirsch, S. R., Arvanitis, L. A., et al. (1997). Quetiapine in patients with schizophrenia. Archives of General Psychiatry, 54, 549-557.
30. Tollefson, G. D., Beasley, C. M., Tamura, R. N., et al. (1997). Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry, 154, 1248-1254.
31. Tollefson, G. D., Beasley, C. M., Tran, P. V., et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
32. Wolters, E. C., Jansen, E. N. H., Tuynman-Qua, H. G., et al. (1996). Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology, 47, 1085-1087.